Business News

    Chimeric Therapeutics (ASX:CHM) announces abstract to be presented at oncology meeting

    Article Image

    Australian clinical stage cell therapy firm Chimeric Therapeutics' (ASX:CHM) Phase 1B trial of its CHM 1101 therapy for glioblastoma has had an abstract chosen for presentation at the American Society of Clinical Oncology.

    The abstract will highlight the clinical trial design and objectives for the trial at the Annual Meeting of the American Society of Clinical Oncology being held in June in Chicago, Illinois. 

    Chimeric Therapeutics says its Chimeric Antigen Receptor therapy uses the peptide component of scorpion venom, chlorotoxin (CLTX), as the tumor-targeting component.

    In preclinical trials, CLTX has demonstrated potential for binding with glioblastoma cells and exhibited potent antitumor activity against the disease.

     

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa